Novo and Viatris settle Ozempic patent suit as generic entry date remains unknown
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster diabetes drug Ozempic.
The Danish company declined to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
